186 related articles for article (PubMed ID: 37954081)
1. Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers.
Fernandez ER; Tamura D; Khan SG; Momen S; Fassihi H; Sarkany R; DiGiovanna JJ; Kraemer KH
Front Oncol; 2023; 13():1282823. PubMed ID: 37954081
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic and Predictive Role of Xeroderma Pigmentosum Gene Expression in Melanoma.
Fischer S; Hamed M; Emmert S; Wolkenhauer O; Fuellen G; Thiem A
Front Oncol; 2022; 12():810058. PubMed ID: 35174087
[TBL] [Abstract][Full Text] [Related]
3. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
4. Skin cancers in patients of skin phototype V or VI with xeroderma pigmentosum type C (XP-C): A retrospective study.
Ventéjou S; Bagny K; Waldmeyer J; Cartault F; Machet L; Osdoit S
Ann Dermatol Venereol; 2019 Mar; 146(3):192-203. PubMed ID: 30853323
[TBL] [Abstract][Full Text] [Related]
5. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm.
Kraemer KH; Lee MM; Andrews AD; Lambert WC
Arch Dermatol; 1994 Aug; 130(8):1018-21. PubMed ID: 8053698
[TBL] [Abstract][Full Text] [Related]
6. Common pathways for ultraviolet skin carcinogenesis in the repair and replication defective groups of xeroderma pigmentosum.
Cleaver JE
J Dermatol Sci; 2000 May; 23(1):1-11. PubMed ID: 10699759
[TBL] [Abstract][Full Text] [Related]
7. Early-onset gynecological tumors in DNA repair-deficient xeroderma pigmentosum group C patients: a case series.
Yurchenko AA; Fresneau B; Borghese B; Rajabi F; Tata Z; Genestie C; Sarasin A; Nikolaev SI
Commun Med (Lond); 2023 Aug; 3(1):109. PubMed ID: 37567969
[TBL] [Abstract][Full Text] [Related]
8. DNA repair protects against cutaneous and internal neoplasia: evidence from xeroderma pigmentosum.
Kraemer KH; Lee MM; Scotto J
Carcinogenesis; 1984 Apr; 5(4):511-4. PubMed ID: 6705149
[TBL] [Abstract][Full Text] [Related]
9. Analysis of point mutations in an ultraviolet-irradiated shuttle vector plasmid propagated in cells from Japanese xeroderma pigmentosum patients in complementation groups A and F.
Yagi T; Tatsumi-Miyajima J; Sato M; Kraemer KH; Takebe H
Cancer Res; 1991 Jun; 51(12):3177-82. PubMed ID: 2039995
[TBL] [Abstract][Full Text] [Related]
10. DNA repair and ultraviolet mutagenesis in cells from a new patient with xeroderma pigmentosum group G and cockayne syndrome resemble xeroderma pigmentosum cells.
Moriwaki S; Stefanini M; Lehmann AR; Hoeijmakers JH; Robbins JH; Rapin I; Botta E; Tanganelli B; Vermeulen W; Broughton BC; Kraemer KH
J Invest Dermatol; 1996 Oct; 107(4):647-53. PubMed ID: 8823375
[TBL] [Abstract][Full Text] [Related]
11. Melanoma and other skin cancers in xeroderma pigmentosum patients and mutation in their cells.
Takebe H; Nishigori C; Tatsumi K
J Invest Dermatol; 1989 May; 92(5 Suppl):236S-238S. PubMed ID: 2715657
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of internal tumors in DNA repair-deficient xeroderma pigmentosum patients: analysis of four international cohorts.
Nikolaev S; Yurchenko AA; Sarasin A
Orphanet J Rare Dis; 2022 Mar; 17(1):104. PubMed ID: 35246173
[TBL] [Abstract][Full Text] [Related]
13. Cockayne syndrome and xeroderma pigmentosum.
Rapin I; Lindenbaum Y; Dickson DW; Kraemer KH; Robbins JH
Neurology; 2000 Nov; 55(10):1442-9. PubMed ID: 11185579
[TBL] [Abstract][Full Text] [Related]
14. Xeroderma pigmentosum and skin cancer.
Daya-Grosjean L
Adv Exp Med Biol; 2008; 637():19-27. PubMed ID: 19181107
[TBL] [Abstract][Full Text] [Related]
15. Persistence of repair proteins at unrepaired DNA damage distinguishes diseases with ERCC2 (XPD) mutations: cancer-prone xeroderma pigmentosum vs. non-cancer-prone trichothiodystrophy.
Boyle J; Ueda T; Oh KS; Imoto K; Tamura D; Jagdeo J; Khan SG; Nadem C; Digiovanna JJ; Kraemer KH
Hum Mutat; 2008 Oct; 29(10):1194-208. PubMed ID: 18470933
[TBL] [Abstract][Full Text] [Related]
16. Psychological correlates of adherence to photoprotection in a rare disease: International survey of people with Xeroderma Pigmentosum.
Walburn J; Canfield M; Norton S; Sainsbury K; Araújo-Soares V; Foster L; Berneburg M; Sarasin A; Morrison-Bowen N; Sniehotta FF; Sarkany R; Weinman J
Br J Health Psychol; 2019 Sep; 24(3):668-686. PubMed ID: 31183946
[TBL] [Abstract][Full Text] [Related]
17. The French Cohort of DNA Repair-Deficient Xeroderma Pigmentosum Patients: Risk of Hematological Malignancies.
Sarasin A
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345043
[TBL] [Abstract][Full Text] [Related]
18. Shining a light on xeroderma pigmentosum.
DiGiovanna JJ; Kraemer KH
J Invest Dermatol; 2012 Mar; 132(3 Pt 2):785-96. PubMed ID: 22217736
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).
Nardin C; Hennemann A; Diallo K; Funck-Brentano E; Puzenat E; Heidelberger V; Jeudy G; Samimi M; Lesage C; Boussemart L; Peuvrel L; Rouanet J; Brunet-Possenti F; Gerard E; Seris A; Jouary T; Saint-Jean M; Puyraveau M; Saiag P; Aubin F
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509227
[TBL] [Abstract][Full Text] [Related]
20. Association between DNA repair-deficiency and high level of p53 mutations in melanoma of Xeroderma pigmentosum.
Spatz A; Giglia-Mari G; Benhamou S; Sarasin A
Cancer Res; 2001 Mar; 61(6):2480-6. PubMed ID: 11289118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
